☰

Robert D. Loberg, Ph.D. - Publications

Affiliations: 
2003 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Animal Physiology Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. Withdrawal: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. The Journal of Biological Chemistry. 298: 102126. PMID 35738192 DOI: 10.1016/j.jbc.2022.102126  0.388
2014 Juan G, Bush TL, Ma C, Manoukian R, Chung G, Hawkins JM, Zoog S, Kendall R, Radinsky R, Loberg R, Friberg G, Payton M. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. Journal of Translational Medicine. 12: 307. PMID 25367255 DOI: 10.1186/S12967-014-0307-X  0.38
2013 Rosen PJ, Lockhart AC, Fu S, Janku F, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg RD, Shubhakar P, Zoog S, Beaupre DM, Lee P. First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 41. PMID 28137005 DOI: 10.1200/Jco.2013.31.6_Suppl.41  0.314
2011 Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. The Journal of Clinical Investigation. 121: 1298-312. PMID 21436587 DOI: 10.1172/Jci43414  0.47
2010 Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, N.Y.). 12: 116-27. PMID 20126470 DOI: 10.1593/Neo.91384  0.509
2009 Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Research. 69: 1685-92. PMID 19176388 DOI: 10.1158/0008-5472.Can-08-2164  0.555
2008 van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta KJ, Loberg RD. CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. Journal of Cellular Biochemistry. 104: 1587-97. PMID 18646053 DOI: 10.1002/Jcb.21652  0.526
2008 Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry. 105: 370-80. PMID 18636554 DOI: 10.1002/Jcb.21835  0.525
2008 Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta KJ, Taichman RS. An in vivo mouse model for human prostate cancer metastasis. Neoplasia (New York, N.Y.). 10: 371-80. PMID 18392141 DOI: 10.1593/Neo.08154  0.496
2008 Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. The Journal of Biological Chemistry. 283: 4283-94. PMID 18057003 DOI: 10.1074/Jbc.M707465200  0.522
2008 Craig M, Ying C, Loberg RD. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. Journal of Cellular Biochemistry. 103: 1-8. PMID 17541941 DOI: 10.1002/Jcb.21379  0.494
2008 Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS. Solid Tumors Target the HSC Niche to Establish Metastatic Footholds in the Marrow Blood. 112: 552-552. DOI: 10.1182/Blood.V112.11.552.552  0.433
2007 Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia (New York, N.Y.). 9: 1030-7. PMID 18084610 DOI: 10.1593/Neo.07778  0.486
2007 Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research. 67: 9417-24. PMID 17909051 DOI: 10.1158/0008-5472.Can-07-1286  0.521
2007 Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. The Journal of Clinical Investigation. 117: 2351-61. PMID 17786228 DOI: 10.1172/Jci31791  0.504
2007 Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (New York, N.Y.). 9: 556-62. PMID 17710158 DOI: 10.1593/Neo.07307  0.551
2007 Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ. The lethal phenotype of cancer: the molecular basis of death due to malignancy. Ca: a Cancer Journal For Clinicians. 57: 225-41. PMID 17626119 DOI: 10.3322/Canjclin.57.4.225  0.412
2007 Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ. PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. Journal of Cellular Biochemistry. 101: 1292-300. PMID 17492768 DOI: 10.1002/Jcb.21252  0.538
2007 Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis Cancer and Metastasis Reviews. 25: 573-587. PMID 17165132 DOI: 10.1007/S10555-006-9019-X  0.487
2006 Giles R, Loberg RD. Can we target the chemokine network for cancer therapeutics? Current Cancer Drug Targets. 6: 659-70. PMID 17168671 DOI: 10.2174/156800906779010245  0.428
2006 Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Reviews. 25: 611-9. PMID 17160712 DOI: 10.1007/S10555-006-9027-X  0.485
2006 Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (New York, N.Y.). 8: 578-86. PMID 16867220 DOI: 10.1593/Neo.06280  0.561
2006 Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia (New York, N.Y.). 8: 69-78. PMID 16533428 DOI: 10.1593/Neo.05679  0.492
2006 Loberg RD, St John LN, Day LL, Neeley CK, Pienta KJ. Development of the VCaP androgen-independent model of prostate cancer. Urologic Oncology. 24: 161-8. PMID 16520280 DOI: 10.1016/J.Urolonc.2005.11.005  0.549
2005 Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology. 66: 1321-6. PMID 16360477 DOI: 10.1016/J.Urology.2005.06.094  0.466
2005 Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8232-41. PMID 16278478 DOI: 10.1200/Jco.2005.03.0841  0.578
2005 Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA, Pienta KJ. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. Journal of Cellular Biochemistry. 96: 641-52. PMID 16052512 DOI: 10.1002/Jcb.20533  0.522
2005 Pienta KJ, Loberg R. The “Emigration, Migration, and Immigration” of Prostate Cancer Clinical Prostate Cancer. 4: 24-30. PMID 15992458 DOI: 10.3816/Cgc.2005.N.008  0.543
2005 Loberg RD, Gayed BA, Olson KB, Pienta KJ. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Journal of Cellular Biochemistry. 96: 439-46. PMID 15988761 DOI: 10.1002/Jcb.20522  0.549
2005 Loberg RD, Neeley CK, Adam-Day LL, Fridman Y, St John LN, Nixdorf S, Jackson P, Kalikin LM, Pienta KJ. Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology International Journal of Oncology. 26: 1699-1705. PMID 15870888 DOI: 10.3892/Ijo.26.6.1699  0.538
2005 Chen BT, Loberg RD, Neeley CK, O'Hara SM, Gross S, Doyle G, Dunn RL, Kalikin LM, Pienta KJ. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology. 65: 616-21. PMID 15780403 DOI: 10.1016/J.Urology.2004.10.053  0.483
2005 Macvicar GR, Loberg RD, Tantivejkul K, Pienta KJ. Growth factor and cytokine antibody array analysis of human hormone refractory prostate cancer (HRPC) tumor specimens and sera Journal of Clinical Oncology. 23: 4686-4686. DOI: 10.1200/Jco.2005.23.16_Suppl.4686  0.482
2005 Loberg RD, Pienta KJ. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer Urologic Oncology-Seminars and Original Investigations. 23: 76. DOI: 10.1016/J.Urolonc.2004.11.005  0.417
2005 Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA, Loberg RD, Pienta KJ. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA) Urologic Oncology-Seminars and Original Investigations. 23: 74. DOI: 10.1016/J.Urolonc.2004.11.002  0.483
2004 Nixdorf S, Grimm MO, Loberg R, Marreiros A, Russell PJ, Pienta KJ, Jackson P. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Letters. 215: 209-20. PMID 15488640 DOI: 10.1016/J.Canlet.2004.05.002  0.361
2004 Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia (New York, N.Y.). 6: 302-9. PMID 15256052 DOI: 10.1593/Neo.03484  0.478
2003 Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology. 62: 128-33. PMID 14747050 DOI: 10.1016/J.Urology.2003.10.026  0.444
Show low-probability matches.